In a blow to its biggest revenue driver, Indivior loses patent battle with generics maker Alvogen

You need a license to cut-and-paste this copyrighted news content.

Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribe

Already a paid subscriber? Sign in to Endpoints News to remove this message.

British drugmaker Indivior watched its stock tumble Friday morning following news that it lost a patent dispute with a rival generics drugmaker, compromising Indivior’s grip on the opioid addiction market.

The issue centers on Indivior’s drug Suboxone, which has long been taken as daily strips that dissolve on the tongue. The drug, which accounts for 80% of Indivior’s revenue, contains a mild opioid that helps stymie withdrawal for opioid addicts.

source: https://endpts.com/in-a-blow-to-its-biggest-revenue-driver-indivior-loses-patent-battle-with-generics-maker-alvogen/